{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasm+of+Colon&page=6", "query": { "condition": "Malignant Neoplasm of Colon", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 1196, "total_pages": 120, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasm+of+Colon&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasm+of+Colon&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T14:46:05.183Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00049608", "title": "Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Lung Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "mistletoe extract", "type": "DIETARY_SUPPLEMENT" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "National Center for Complementary and Integrative Health (NCCIH)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2002-07", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-10-07T14:46:05.183Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00049608" }, { "nct_id": "NCT06385925", "title": "A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Neoplasm" ], "interventions": [ { "name": "TSN1611", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tyligand Pharmaceuticals (Suzhou) Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 440, "start_date": "2024-04-29", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-10-07T14:46:05.183Z", "location_count": 3, "location_summary": "Houston, Texas • San Antonio, Texas • Fairfax, Virginia", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06385925" }, { "nct_id": "NCT03745326", "title": "Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastrointestinal Cancer", "Pancreatic Cancer", "Gastric Cancer", "Colon Cancer", "Rectal Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "anti-Kirsten rat sarcoma virus (KRAS) Glycine(G) to Aspartic Acid(D) substitution at codon 12 peripheral blood lymphocytes (PBL)", "type": "BIOLOGICAL" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "CT", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "PET", "type": "DIAGNOSTIC_TEST" }, { "name": "Chest x-ray", "type": "DIAGNOSTIC_TEST" }, { "name": "Photography", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 5, "start_date": "2019-05-16", "completion_date": "2022-08-23", "has_results": true, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-10-07T14:46:05.183Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03745326" }, { "nct_id": "NCT06269978", "title": "Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colorectal Carcinoma", "Metastatic Malignant Neoplasm in the Peritoneum", "Stage IV Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Diagnostic Laparoscopy", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Surgical Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Arjun Mittra", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2024-12-31", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-07T14:46:05.183Z", "location_count": 2, "location_summary": "Columbus, Ohio • Dallas, Texas", "locations": [ { "city": "Columbus", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06269978" }, { "nct_id": "NCT05961709", "title": "The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Cancer" ], "interventions": [ { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2024-05-20", "completion_date": "2028-04-30", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-07T14:46:05.183Z", "location_count": 5, "location_summary": "Gilbert, Arizona • Jacksonville, Florida • New Orleans, Louisiana + 2 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Camden", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05961709" }, { "nct_id": "NCT07321106", "title": "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Colorectal Cancer (CRC)", "Colorectal (Colon or Rectal) Cancer", "CRC", "Metastatic Colon Cancer", "Colon Cancer", "Advanced Colorectal Cancer" ], "interventions": [ { "name": "CBI-1214", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Cartography Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2026-01-15", "completion_date": "2029-10", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-07T14:46:05.183Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Duarte, California • Los Angeles, California + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07321106" }, { "nct_id": "NCT01623258", "title": "A Prospective Randomized Study Comparing Sentinel Lymph Node (SLN) Evaluation With Standard Pathological Evaluation for the Staging of Colon Carcinoma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colon Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Walter Reed Army Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2002-12", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2012-06-19", "last_synced_at": "2026-10-07T14:46:05.183Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01623258" }, { "nct_id": "NCT01643499", "title": "Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acinar Cell Adenocarcinoma of the Pancreas", "Adenocarcinoma of the Gallbladder", "Adenocarcinoma of Unknown Primary", "Adult Primary Cholangiocellular Carcinoma", "Advanced Adult Primary Liver Cancer", "Cholangiocarcinoma of the Extrahepatic Bile Duct", "Cholangiocarcinoma of the Gallbladder", "Diffuse Adenocarcinoma of the Stomach", "Duct Cell Adenocarcinoma of the Pancreas", "Intestinal Adenocarcinoma of the Stomach", "Localized Unresectable Adult Primary Liver Cancer", "Metastatic Carcinoma of Unknown Primary", "Metastatic Extrahepatic Bile Duct Cancer", "Mixed Adenocarcinoma of the Stomach", "Mucinous Adenocarcinoma of the Colon", "Mucinous Adenocarcinoma of the Rectum", "Newly Diagnosed Carcinoma of Unknown Primary", "Signet Ring Adenocarcinoma of the Colon", "Signet Ring Adenocarcinoma of the Rectum", "Stage III Pancreatic Cancer", "Stage IIIA Colon Cancer", "Stage IIIA Gallbladder Cancer", "Stage IIIA Gastric Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Gallbladder Cancer", "Stage IIIB Gastric Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Gastric Cancer", "Stage IIIC Rectal Cancer", "Stage IV Gastric Cancer", "Stage IV Pancreatic Cancer", "Stage IVA Colon Cancer", "Stage IVA Gallbladder Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Gallbladder Cancer", "Stage IVB Rectal Cancer", "Unresectable Extrahepatic Bile Duct Cancer" ], "interventions": [ { "name": "oxaliplatin", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2012-03-26", "completion_date": "2019-07", "has_results": false, "last_update_posted_date": "2020-05-08", "last_synced_at": "2026-10-07T14:46:05.183Z", "location_count": 2, "location_summary": "Chicago, Illinois • Evanston, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01643499" }, { "nct_id": "NCT00060411", "title": "A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mucinous Adenocarcinoma of the Colon", "Mucinous Adenocarcinoma of the Rectum", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Signet Ring Adenocarcinoma of the Colon", "Signet Ring Adenocarcinoma of the Rectum", "Stage IIIA Colon Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Rectal Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2003-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-10-07T14:46:05.183Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060411" }, { "nct_id": "NCT03480152", "title": "Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Colon Cancer", "Gastrointestinal Cancer", "Genitourinary Cancer", "Hepatocellular Cancer" ], "interventions": [ { "name": "National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 5, "start_date": "2018-05-18", "completion_date": "2019-11-05", "has_results": true, "last_update_posted_date": "2020-06-02", "last_synced_at": "2026-10-07T14:46:05.183Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03480152" } ] }